Real-world treatment patterns of benralizumab therapy for patients with severe asthma
Bibliographic record
Abstract
<b>Introduction:</b> As many as 8% of patients with asthma in Canada have severe disease (Asthma Society of Canada, 2014). Patients with severe, eosinophilic asthma may benefit from a biologic therapy to improve asthma control. Benralizumab is an anti–IL-5Rɑ biologic approved in Canada in February 2018 for add-on maintenance therapy for severe eosinophilic asthma. <b>Objective:</b> We sought to describe time to benralizumab discontinuation for Canadian patients initiating therapy for severe eosinophilic asthma. <b>Methods:</b> This analysis is an early phase of the Canadian contribution to the XALOC global multi-country real-world evidence program. Administrative data were extracted from a convenience sample of 136 injection clinics across Canada for patients initiating therapy between April 2018 and May 2019. Patients with ≥1 injection(s) of benralizumab were included in the analysis. Discontinuation was defined as the time of last injection if no further treatment was given within 90 days. Patients with pending appointments were censored at end of follow up. Kaplan-Meier survival analyses were used to describe the time to discontinuation, stratified by prior biologic exposure. <b>Results:</b> Data were available for 2,657 patients with a mean age of 56.7 years (SD 14.1). The proportion of patients who discontinued at 6 months post treatment initiation was 8% (95% CI 7.2–9.7%) and 15% (95% CI 13.2–17.4%) at 12 months. No significant difference in probability of discontinuation was noted by prior biologic exposure. <b>Conclusion:</b> Of patients initiating benralizumab, 85% remained on treatment for at least 12 months. Future research is needed to detail the clinical rationale for real-world discontinuation of treatment.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".